Granted Patent
B2
US 12,329,726 · App. 17/954,858 · Granted Jun 17, 2025
Biomarkers for efficacy of prophylactic treatments against stress-induced affective disorders
Inventors:
Josephine Cecelia McGowan (New York, NY); Christine Ann Denny (Ho-Ho-Kus, NJ); Michael Kiebish (Framingham, MA)
Assignees:
The Trustees of Columbia University in the City of New York; BPG BIO, INC; The Research Foundation for Mental Hygiene, Inc
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Biomarkers for assessing the efficacy of prophylactic treatments of stress-induced affective disorders are provided.
Claims (23)
1. A method for treating a subject for a stress-induced affective disorder or stress-induced psychopathology, the method comprising:
(a) administering or having administered a prophylactic treatment to the subject prior to a stressor, wherein the prophylactic treatment comprises an effective amount of a pharmaceutic composition comprising ketamine, or a pharmaceutically acceptable salt thereof;
(b) determining level of one or more biomarkers in a biological sample obtained from the subject after step (a) and after the stressor, wherein the one or more biomarkers are selected from the group consisting of adenine, adenosine monophosphate (AMP), adenosine triphosphate (ATP), D-ribose 5-phosphate, D-ribulose 5-phosphate, guanosine monophosphate, guanosine diphosphate, hypoxanthine, inosine, phosphoribosyl pyrophosphate, dihydrothymine, uridine 5-monophosphate, and uridine-diphosphate, 5,6-dihydrouridine, serine, glutamic acid, gamma-aminobuytric acid (GABA), 5-hydroxy-L-tryptophan (5-HTP), O-phosphoethanolamine (PE), N-acetyl-L-tyrosine, and combinations thereof; and
(c) comparing the level obtained in step (b) with the level of the one or more biomarkers in a control sample,
wherein the stress-induced affective disorder or stress-induced psychopathology is selected from the group consisting of: depressive-like behavior and associated affective disorders, anhedonic behavior and associated affective disorders, anxiety and associated affective disorders, cognitive impairments and deficits and associated disorders, and combinations thereof.
2. The method of claim 1 , further comprising maintaining a treatment regime or determining the prophylactic treatment as being effective, when the level of one or more biomarkers increases or decreases by at least 10% compared to its level in the control sample.
3. The method of claim 1 , further comprising adjusting a treatment regime, when the level of one or more biomarkers is unchanged, or increases or decreases by less than 10%, compared to its level in the control sample.
4. The method of claim 1 , wherein the one or more biomarkers are selected from the group consisting of purines, purine metabolites, purine precursors, purine derivatives, pyrimidines, pyrimidine metabolites, pyrimidine precursors, pyrimidine derivatives, nucleotides, nucleotide metabolites, nucleotide precursors, nucleotide derivatives, neurotransmitters, neurotransmitter metabolites, neurotransmitter precursors, neurotransmitter derivatives, and combinations thereof.
5. The method of claim 1 , wherein the one or more biomarkers the neurotransmitters are inhibitory neurotransmitters or excitatory neurotransmitters.
6. The method of claim 1 , wherein the one or more biomarkers the neurotransmitters are amino acid-derived neurotransmitters.
7. The method of claim 1 , wherein the one or more biomarkers are selected from the group consisting of adenine, adenosine monophosphate (AMP), adenosine triphosphate (ATP), D-ribose 5-phosphate, D-ribulose 5-phosphate, guanosine monophosphate, guanosine diphosphate, hypoxanthine, inosine, phosphoribosyl pyrophosphate, and combinations thereof.
8. The method of claim 1 , wherein the one or more biomarkers are selected from the group consisting of dihydrothymine, uridine 5-monophosphate, and uridine-diphosphate, 5,6-dihydrouridine, and combinations thereof.
9. The method of claim 1 , wherein the one or more biomarkers are selected from the group consisting of serine, glutamic acid, gamma-aminobuytric acid (GABA), 5-hydroxy-L-tryptophan (5-HTP), O-phosphoethanolamine (PE), N-acetyl-L-tyrosine, and combinations thereof.
10. The method of claim 1 , wherein the pharmaceutic composition is administered to the subject about 48 hours to about 3 weeks prior to a stressor.
11. The method of claim 1 , wherein the pharmaceutic composition is administered orally, intravenously, intranasally, or via injection to the subject.
12. The method of claim 1 , wherein the pharmaceutic composition comprises norketamine, hydroxyketamines, dehydronorketamine, and/or hydroxynorketamine (HNK).
13. The method of claim 1 , wherein the pharmaceutic composition comprises (2R,6R)-HNK and/or (2S,6S)-HNK.
14. The method of claim 1 , wherein the pharmaceutic composition is administered to the subject about 1 week prior to the stressor.
15. The method of claim 1 , wherein the pharmaceutic composition is administered to the subject once prior to the stressor.
16. The method of claim 1 , wherein the pharmaceutic composition is administered intranasally to the subject.
17. The method of claim 1 , wherein the increase or decrease in the level of the one or more biomarkers ranges from about 30% to about 3-fold.
18. The method of claim 1 , wherein the biological sample is a plasma, serum, blood or urine sample, or a combination thereof.
19. The method of claim 1 , wherein the subject is a human.
Assignments (4)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 14, 2024
From: BERG LLC
To: BPG BIO, INC.
Reel/Frame 069259/0947 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 2, 2022
From: MCGOWAN, JOSEPHINE CECELIA
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK
Reel/Frame 061957/0747 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 2, 2022
From: DENNY, CHRISTINE ANN
To: THE TRUSTEES OF COLUMBIA UNIVERSITY IN THE CITY OF NEW YORK; THE RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC.
Reel/Frame 061957/0756 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Dec 2, 2022
From: KIEBISH, MICHAEL
To: BERG LLC
Reel/Frame 061957/0846 →
Continuity (3)
Continuation
16761548
Provisional Application
62583734
· Nov 9, 2017
References Cited (207)
US 3254124A
· Stevens
· 1966
[cited by applicant]
US 6727231B1
· Page et al.
· 2004
[cited by applicant]
US 8785500B2
· Charney et al.
· 2014
[cited by applicant]
US 9801865B2
· Moran
· 2017
[cited by applicant]
US 20040067963A1
· Shapira et al.
· 2004
[cited by applicant]
US 20040138298A1
· Mermelstein et al.
· 2004
[cited by applicant]
US 20090105222A1
· Kranzler et al.
· 2009
[cited by applicant]
US 20090170899A1
· Debonnel et al.
· 2009
[cited by applicant]
US 20110213219A1
· Bilello et al.
· 2011
[cited by applicant]
US 20110218213A1
· Royster, Jr.
· 2011
[cited by applicant]
US 20130236573A1
· Singh et al.
· 2013
[cited by applicant]
US 20140057988A1
· Weg
· 2014
[cited by applicant]
US 20160067196A1
· Charney et al.
· 2016
[cited by applicant]
US 20170007618A1
· Goosens et al.
· 2017
[cited by applicant]
US 20190046506A1
· Friedhoff et al.
· 2019
[cited by applicant]
US 20190046554A1
· Deisseroth et al.
· 2019
[cited by applicant]
JP 2012013415A
· 2012
[cited by applicant]
WO 2003020275A1
· 2003
[cited by applicant]
WO 2008118785A2
· 2008
[cited by applicant]
WO 2013056229A1
· 2013
[cited by applicant]
WO 2013149102A1
· 2013
[cited by applicant]
WO 2014020155A1
· 2014
[cited by applicant]
WO 2014045023A1
· 2014
[cited by applicant]
WO 2014169272A1
· 2014
[cited by applicant]
WO 2014171826A1
· 2014
[cited by applicant]
WO 2015037248A1
· 2015
[cited by applicant]
WO 2015121166A1
· 2015
[cited by applicant]
WO 2016025581A1
· 2016
[cited by applicant]
WO 2016047677A1
· 2016
[cited by applicant]
WO 2017082103A1
· 2016
[cited by applicant]
WO 2017003935A1
· 2017
[cited by applicant]
WO 2017087691A1
· 2017
[cited by applicant]
WO 2018109935A1
· 2018
[cited by applicant]
WO 2018222781A2
· 2018
[cited by applicant]
Zarate et al. A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression. Arch Gen Psychiatry_ 2006; 63(8):856-64.
[cited by applicant]
Zarate et al., “Relationship of ketamine's plasma metabolites with response, diagnosis, and side effects in major depression”, Biol Psychiatry_ 2012; 72(4):331-8.
[cited by applicant]
Zarate et al., “Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial”, Biol Psychiatry. 2012; 71 (11):939-46.
[cited by applicant]
Zhang et al., “R (−)-ketamine shows greater potency and longer lasting antidepressant effects than S +)-ketamine”, harmacol Biochem Behav_ 2014; 116:137-41.
[cited by applicant]
Zheng et al., “Identification and validation of urinary metabolite biomarkers for major depressive disorder”, Mol Cell Proteomics. Jan. 2013;12(1):207-14.
[cited by applicant]
Parise Eric M et al: “Repeated Ketamine Exposure Induces an Enduring Resilient Phenotype in Adolescent and Adult Rats”, Biological Psychiatry, 2013, vol. 74, No. 10, pp. 750-759.
[cited by applicant]
Park et al., “Purine and pyrimidine metabolism: Convergent evidence on chronic antidepressant treatment response in mice and humans”, Sci Rep. Oct. 12, 2016;6:35317.
[cited by applicant]
Paul et al., “(R,S)-Ketamine metabolites (R,S)-norketamine and (2S,6S)-hydroxynorketamine increase the mammalian target of rapamycin function”, Anesthesiology_ 2014; 121(1): pp. 149-159.
[cited by applicant]
Pehrson et al., “Altered γ-aminobutyric acid neurotransmission in major depressive disorder: a critical review of the supporting evidence and the influence of serotonergic antidepressants”, Drug Des Devel Ther. Jan. 19,…
[cited by applicant]
Peselow et al., “Prophylactic efficacy of fluoxetine, escitalopram, sertraline, paroxetine, and concomitant psychotherapy in major depressive disorder: outcome after long-term follow-up”. Psychiatry Res. Feb. 28, 2015;2…
[cited by applicant]
Pham et al., “Common Neurotransmission Recruited in (R,S)-Ketamine and (2R,6R)-Hydroxynorketamine-Induced Sustained Antidepressant-like Effects”, Biol Psychiatry 2018; 84 (1): e3-e6.
[cited by applicant]
Piccinelli et al., “Gender differences in depression. Critical review”, Br J Psychiatry. 2000; 177: pp. 486-492.
[cited by applicant]
Pittig et al., “The role of associative fear and avoidance learning in anxiety disorders: Gaps and directions for future research”, Neurosci Biobehav Rev. May 2018;88:117-140.
[cited by applicant]
Porsolt et al., “Depression: a new animal model sensitive to antidepressant treatments”, Nature 1977; 266(5604): 730-732.
[cited by applicant]
Price et al. “Effects of intravenous ketamine on explicit and implicit measures of suicidality in treatment-resistant depression.” Biological psychiatry vol. 66,5 (2009): 522-6.
[cited by applicant]
Rachel Yarmolinsky, Could a Dose of Ketamine Prevent Psychiatric Disorders Such As PTSD?, Columbia University Department of Psychiatry, Jul. 2, 2015 [retrieved from https://www.columbiapsychiatry.org/news/could-dose-ket…
[cited by applicant]
Ramaekers et al., “Clinical recognition and aspects of the cerebral folate deficiency syndromes”, Clin Chem Lab Med. Mar. 1, 2013;51(3):497-511.
[cited by applicant]
Ramirez et al., “Activating positive memory engrams suppresses depression-like behaviour”, Nature 522, 335-339 (2015).
[cited by applicant]
Rasmussen et al., “Serial infusions of low-dose ketamine for major depression”, J Psychopharmacol. 2013; 27 (5):444-50.
[cited by applicant]
Reardon, Rave drug holds promise for treating depression fast, Nature, 517, 130-131 (2015).
[cited by applicant]
Redei et al., “Blood transcriptomic biomarkers in adult primary care patients with major depressive disorder undergoing cognitive behavioral therapy”, Transl Psychiatry. Sep. 16, 2014;4(9).
[cited by applicant]
Richardson-Jones JW, Craige CP, Guiard BP, Stephen A, Metzger KL, Kung HF, et al. (2010): 5-HT1A Autoreceptor Levels Determine Vulnerability to Stress and Response to Antidepressants. Neuron 65(1): 40-52.
[cited by applicant]
Rissman et al., “Estrogen receptors are essential for female sexual receptivity”, Endocrinology_ 1997; vol. 138 (1):507-10.
[cited by applicant]
Rotroff et al., “Metabolomic signatures of drug response phenotypes for ketamine and esketamine in subjects with refractory major depressive disorder: New mechanistic insights for rapid acting antidepressants”, Sep. 201…
[cited by applicant]
Saland et al., “Hedonic sensitivity to low-dose ketamine is modulated by gonadal hormones in a ?ex-dependent manner”, Sci Rep_ 2016; 6.
[cited by applicant]
Saxe et al., “Ablation of hippocampal neurogenesis mpairs contextual fear conditioning and synaptic plasticity in the dentate gyrus”, Proc Natl Acad Sci 2006; 103( 46): H501-17506.
[cited by applicant]
Schiller D, Monfils MH, Raio CM, Johnson DC, LeDoux JE, Phelps EA (2010): Preventing the return of fear in humans using reconsolidation update mechanisms. Nature 463:49-53.
[cited by applicant]
Serafini G, Howland RH, Rovedi F, Girardi P, Amore M. The Role of Ketamine in Treatment-Resistant Depression: A Systematic Review. Curr Neuropharmacol. 2014; 12(5):444-61.
[cited by applicant]
Serchov et al., “Increased Signaling via Adenosine A1 Receptors, Sleep Deprivation, Imipramine, and Ketamine Inhibit Depressive-like Behavior via Induction of Homer1a”, Neuron. Aug. 5, 2015;87(3):549-62.
[cited by applicant]
Shansky et al., “Estrogen promotes stress sensitivity in a prefrontal cortex-amygdala pathway”, Cerebral cortex (New York, NY: 1991) 2010; 20(11): 2560-2567.
[cited by applicant]
Shin et al., “The neurocircuitry of fear, stress, and anxiety disorders”, Neuropsychopharmacology. Jan. 2010;35 (1):169-91.
[cited by applicant]
Shirayama et al., “R-ketamine: a rapid-onset and sustained antidepressant without psychotomimetic side effects”, Transl Psychiatry. Sep. 1, 2015;5(9):e632.
[cited by applicant]
Singh et al., “Intravenous Esketamine in Adult Treatment-Resistant Depression: A Double-Blind, DoubleRandomization, Placebo-Controlled Study”, Biol Psychiatly 2016; 80(6): 424-431.
[cited by applicant]
Soldin et al., “Sex differences in pharmacokinetics and pharmacodynamics”, Clin Pharmacokinet 2009; 48 (3): 143-157.
[cited by applicant]
Soumier et al., “New Hippocampal Neurons Mature Rapidly in Response to Ketamine But Are Not Required for Its Acute Antidepressant Effects on Neophagia in Rats”, eNeuro_ 2016; 3(2).
[cited by applicant]
Strom et al., “Ovariectomy and 17β-estradiol Replacement in Rats and Mice: A Visual Demonstration”, Journal of Visualized Experiments, 2012 (64):e4013.
[cited by applicant]
Sugiyama et al., “Systemic administration of a delta opioid receptor agonist, KNT-127, facilitates extinction learning of fear memory in rats”, J Pharmacol Sci. Mar. 2019;139(3):174-179.
[cited by applicant]
Supplementary European Search Report in corresponding European Application EP 16867149.3, dated Nov. 6, 2019.
[cited by applicant]
Suzuki, K., Nosyreva, E., Hunt, K. et al. Effects of a ketamine metabolite on synaptic NMDAR function. Nature 546, E1-E3 (2017).
[cited by applicant]
Tabak et al., “Interaction of CD38 Variant and Chronic Interpersonal Stress Prospectively Predicts Social Anxiety and Depression Symptoms Over Six Years”, Clin Psychol Sci. Jan. 1, 2016;4(1):17-27.
[cited by applicant]
Thelen et al., “Repeated ketamine treatment induces sex-specific behavioral ?nd neurochemical effects in mice”, Behav Brain Res_ 2016; 312:305-12.
[cited by applicant]
Trouch S, Sasaki JM, Tu T, Reijmers LG (2013): Fear extinction causes target-specific remodeling of perisomatic inhibitory synapses. Neuron 80:1054-1065.
[cited by applicant]
Unknown, “Blood test unlocks new frontier in treating depression”, Science Daily, Mar. 29, 2017.
[cited by applicant]
Van't Veer et al., “Role of kappa-opioid receptors in stress and anxiety-related behavior.” Psychopharmacology vol. 229,3 (2013): 435-52.
[cited by applicant]
Watanabe et al., “Gene expression-based biological test for major depressive disorder: an advanced study”, Neuropsychiatr Dis Treat. Feb. 21, 2017;13:535-541.
[cited by applicant]
Waxman et al., “Sex differences in the expression of hepatic drug metabolizing enzymes”, Mol Pharmacol 2009; 76(2): 215-228.
[cited by applicant]
Weckmann et al., “Time-dependent metabolomic profiling of Ketamine drug action reveals hippocampal pathway alterations and biomarker candidates”, Transl Psychiatry. Nov. 11, 2014;4(11).
[cited by applicant]
WHO. Depression Fact Sheet. World Health Organization. 2017.
[cited by applicant]
Womble, AL, “Effects of Ketamine on Major Depressive Disorder in a Patient with Posttraumatic Stress Disorder,” AANA Journal, Apr. 2013, vol. 81, No. 2, pp. 118-119.
[cited by applicant]
Wood et al., “Acute toxicity associated with the recreational use of the ketamine derivative methoxetamine”, European Journal of Clinical Pharmacology, 68(5), 853-856, 2012.
[cited by applicant]
World Health Organization. List of Essential Medicines. Adults: 19th Edition. Apr. 2015.
[cited by applicant]
Yamaguchi et al., “(2R,6R)-Hydroxynorketamine is not essential for the antidepressant actions of (R)-ketamine in mice”, Neuropsychopharmacology, 2018.
[cited by applicant]
Yang et al. “Potential metabolite markers of schizophrenia.” Molecular psychiatry vol. 18,1 (2013): 67-78. doi:10.1038/mp.2011.131.
[cited by applicant]
Zanos et al., “NMDAR inhibition-independent antidepressant actions of ketamine metabolites”, Nature_ 2016; 533 (7604):481-6.
[cited by applicant]
Zarate et al, Ketamine for depression: evidence, challenges and promise, World Psychiatry. 2015;14(3):348-50.
[cited by applicant]
Faye et al., “Rapid anxiolytic effects of a serotonin type 4 receptor agonist involve prefrontal cortex/brainstem neural circuit recruitment”, European Neuropsychopharmacology, vol. 28, Supplement 1, 2018, pp. S21-S22.
[cited by applicant]
Official Action issued in CN Pat. App. No. 2020800422524 dated Aug. 8, 2023.
[cited by applicant]
A1-Harbi KS. Treatment-resistant depression: therapeutic trends, challenges, and future directions. Patient Prefer Adherence. 2012; 6:369-88.
[cited by applicant]
Abdallah et al., “Glutamate Metabolism in Major Depressive Disorder”, The American Journal of Psychiatry, 171(12), 1320-1327, 2014.
[cited by applicant]
Abdallah et al., “Ketamine and rapid-acting antidepressants: a window into a new neurobiology for mood disorder therapeutics”, Annu Rev Med. 2015; 66: pp. 509-523.
[cited by applicant]
Adriana Feder et al: “Efficacy of Intravenous Ketamine for Treatment of Chronic Posttraumatic Stress Disorder A Randomized Clinical Trial”, JAMA Psychi, 2014, vol. 71, No. 6, pp. 681-688.
[cited by applicant]
Al Shirawi MI, Kennedy SH, Ho KT, Byrne R, Downar J. Oral Ketamine in Treatment-Resistant Depression: A Clinical Effectiveness Case Series. J Clin Psychopharmacol. 2017; 37(4):464-7.
[cited by applicant]
Aleksandrova et al., “Antidepressant effects of ketamine and the roles of AMPA glutamate receptors and other mechanisms beyond NMDA receptor antagonism”, J Psychiatry Neurosci 2017; 42(4): 222-229.
[cited by applicant]
Alquraan et al., “Omega-3 Fatty Acids Prevent Post-Traumatic Stress Disorder-Induced Memory Impairment”, Biomolecules. Mar. 12, 2019;9(3):100.
[cited by applicant]
Altemus et al., “Sex differences in anxiety and depression clinical perspectives”, Front Neuroendocrinol 2014; 35(3): 320-330.
[cited by applicant]
Amat et al., “Previous Ketamine Produces an Enduring Blockade of Neurochemical and Behavioral Effects of Uncontrollable Stress”, J Neuro_ 2016; 36(1):153-61.
[cited by applicant]
Author Unknown, “Blood test unlocks new frontier in treating depression”, UT Southwestern Medical Center, Mar. 29, 2017, last downloaded from https://www.sciencedaily.com/releases/2017/03/170329145732.htm on Nov. 23, 20…
[cited by applicant]
Autry AE, Adachi M, Nosyreva E, Na ES, Los MF, Cheng PF, et al. (2011): NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses. Nature 475:91-95.
[cited by applicant]
Averill et al., “Glutamate dysregulation and glutamatergic therapeutics for PTSD: Evidence from human studies”, Neurosci Lett. May 10, 2017;649:147-155.
[cited by applicant]
Bach et al., “Blocking human fear memory with the matrix metalloproteinase inhibitor doxycycline”, Mol Psychiatry. Jul. 2018;23(7):1584-1589.
[cited by applicant]
Baratta et al., “Stress Enables Reinforcement-Elicited Serotonergic Consolidation of Fear Memory”, Biol Psychiatry. May 15, 2016;79(10):814-822.
[cited by applicant]
Bartoli et al., “Metabolic syndrome in people suffering from posttraumatic stress disorder: a systematic review and meta-analysis”, Metab Syndr Relat Disord. Oct. 2013;11(5):301-8.
[cited by applicant]
Brachman et al., “Ketamine as a prophylactic against stress-induced depressive-like behavior”, Biol Psychiatry. 2016, 79 (9): 776-786.
[cited by applicant]
Brachman et al., “A single injection of ketamine confers robust, long-term protection against stress-induced depressive-like behaviors”, Society for Neuroscience conference, Presentation Abstract on Nov. 17, 2014.
[cited by applicant]
Brent Miles as told to Troy Farah, I Used Ketamine to Treat My Depression, Vice, Jan. 15, 2015 [retrieved from https://www.vice.com/en_us/article/4w7eyd/i-used-ketamine-to-treat-my-depression-122].
[cited by applicant]
Browne CA, Lucki I. Antidepressant effects of ketamine: mechanisms underlying fastacting novel antidepressants. Front Pharmacol. 2013; 4.
[cited by applicant]
Caddy C, Giaroli G, White TP, Shergill SS, Tracy DK (2014): Ketamine as the prototype glutamatergic antidepressant: Pharmacodynamic actions, and a systematic review and meta-analysis of efficacy. Ther Adv Psychopharmaco…
[cited by applicant]
Carrier N, Kabbaj M. Sex differences in the antidepressant-like effects of ketamine. Neuropharmacology _ 2013; 170:27-34.
[cited by applicant]
Cattaneo et al., “Absolute Measurements of Macrophage Migration Inhibitory Factor and Interleukin-1-β mRNA Levels Accurately Predict Treatment Response in Depressed Patients”, Int J Neuropsychopharmacol. Sep. 30, 2016;1…
[cited by applicant]
Chen et al., “Ovarian hormones mediate the prophylactic efficacy of (R,S)-ketamine and (2R,6R)-hydroxynorketamine in female mice”, bioRxiv, 712752, Jul. 24, 2019.
[cited by applicant]
Christine Denny, “Analysis of the role of hippocampal adult-born neurons in behavior and physiology”, NIH Grant #:5F31MH084529-03, Budget Start Jul. 1, 2011, Budget End Jun. 30, 2012.
[cited by applicant]
Christine Denny, “Optogenetic dissection of hippocampal circuitry underlying Alzheimers disease”, NIH Grant #:1DP5OD017908-01, Budget Start Sep. 19, 2013, Budget End Aug. 31, 2014.
[cited by applicant]
Cieślak et al., “The roles of purinergic signaling in psychiatric disorders”, Acta Biochim Pol. 2016;63(1):1-9.
[cited by applicant]
Clinical Trial #: NCT02019654, “An investigation of the biological and neuronal mechanisms of post traumatic stress disorder, depression and post-concussive syndrome onset following a traumatic brain injury”, Sponsor: N…
[cited by applicant]
Clinical Trial #: NCT02517190, “Effects of repeated short-term microgravity during parabolic flight conditions on neuro- endocrine, immune and metabolic changes (COSI@PFC)”, Sponsor: University Hospital, Caen, Jul. 23, …
[cited by applicant]
ClinicalTrials.gov, Rapid Antidepressant Effects of Ketamine in Major Depression, National Institute of Mental Health (NIMH), Identifier: NCT00088699 [retrieved from https://clinicaltrials.gov/ct2/show/NCT00088699; Firs…
[cited by applicant]
Dalla et al., “Females do not Express Learned Helplessness like Males do”, Neuropsychopharmacology _ 2007; 33(7): 1559-69.
[cited by applicant]
Daly et al., “Efficacy and Safety of Intranasal Esketamine Adjunctive to Oral Antidepressant Therapy in Treatment Resistant Depression: A Randomized Clinical Trial”, JAMA 2018, 75(2): 139-148.
[cited by applicant]
David DJ, Samuels BA, Rainer Q,Wang JW, Marsteller D, Mendez I, et al. (2009): Neurogenesis-dependent and -independent effects of fluoxetine in an animal model of anxiety/depression. Neuron 62:479-493.
[cited by applicant]
Davidson RJ, Pizzagalli D, Nitschke JB, Putnam K. Depression: perspectives from affective neuroscience. Ann Rev Psychology_ 2002; 53:545-74.
[cited by applicant]
De Souza et al., “Posttraumatic stress disorder-type behaviors in streptozotocin-induced diabetic rats can be prevented by prolonged treatment with vitamin E”, Behav Brain Res. Feb. 1, 2019;359:749-754.
[cited by applicant]
Denny CA, Burghardt NS, Schachter DM, Hen R, Drew MR (2012): 4- to 6-week-old adult-born hippocampal neurons influence novelty-evoked exploration and contextual fear conditioning. Hippocampus 22:1188-1201.
[cited by applicant]
Denny et al., “Hippocampal Memory Traces Are Differentially Modulated by Experience, Time, and Adult Neurogenesis”, Neuron. 2014; 83(1):189-201.
[cited by applicant]
Diazgranados et al., “A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression”, Arch Gen Psychiatry. Aug. 2010;67(8):793-802.
[cited by applicant]
Dolzani et al., “Inhibition of a Descending Prefrontal Circuit Prevents Ketamine-Induced Stress Resilience in Females”, eNeuro 2018; 5(1).
[cited by applicant]
Domino, EF, “Taming the Ketamine Tiger,” Anesthesiology, 2010, vol. 113, pp. 678-686.
[cited by applicant]
Donahue RJ, Muschamp JW, Russo SJ, Nestler EJ, Carlezon WA Jr (2014): Effects of striatal deltaFosB overexpression and ketamine on social defeat stress-induced anhedonia in mice. Biol Psychiatry 76:550-558.
[cited by applicant]
Dossat et al., “Behavioral and biochemical sensitivity to low doses of ketamine: influence of estrous cycle in C57BU6 mice”, Neuropharmacology 2018; 130: 30-41.
[cited by applicant]
Drew et al., “Arrest of adult hippocampal neurogenesis in mice impairs single- but not multiple-trial contextual fear conditioning”, Behav Neurosci. 2010; 124(4):446-54.
[cited by applicant]
Dulawa SC, Holick KA, Gundersen B, Hen R (2004): Effects of chronic fluoxetine in animal models of anxiety and depression. Neuropsychopharmacology 29:1321-1330.
[cited by applicant]
Dunlop et al., “The hypothalamic-pituitary-adrenal axis in PTSD: Pathophysiology and treatment interventions”, Prog Neuropsychopharmacol Biol Psychiatry. Mar. 8, 2019;89:361-379.
[cited by applicant]
E.D. Ballard et al., Improvement in suicidal ideation after ketamine infusion: Relationship to reductions in depression and anxiety, J. Psychiatry Research vol. 58 pp. 161-166 Nov. 2014.
[cited by applicant]
Elhabazi et al., “Assessment of morphine-induced hyperalgesia and analgesic tolerance in mice using thermal and mechanical nociceptive modalities”, J Vis Exp. Jul. 29, 2014;(89).
[cited by applicant]
Flory JD, Yehuda R. Comorbidity between post-traumatic stress disorder and major depressive disorder: alternative explanations and treatment considerations. Dialogues Clin Neurosci. 2015; 17(2):141-50.
[cited by applicant]
Franceschelli et al.: “Sex differences in the rapid and the sustained antidepressant-like effects of ketamine in stress-naïve and “depressed” mice exposed to chronic mild stress”, Neuroscience. Apr. 2, 2015;290:49-60.
[cited by applicant]
Fukumoto et al., “Antidepressant Potential of (R)-Ketamine in Rodent Models: Comparison with (S)-Ketamine”, J Pharmacol Exp Ther. Apr. 2017;361(1):9-16.
[cited by applicant]
Gardier et al., “Ketamine as a prophylactic against stress-induced depressive-like behavior”, Biol Psychiatry, vol. 79 (9), p. 776-86, May 2016.
[cited by applicant]
Hammack SE, Cooper MA, Lezak KR (2012): Overlapping neurobiology of learned helplessness and conditioned defeat: Implications for PTSD and mood disorders. Neuropharmacology 62:565-575.
[cited by applicant]
Hasler et al., “Reduced Prefrontal Glutamate/Glutamine and γ-Aminobutyric Acid Levels in Major Depression Determined Using Proton Magnetic Resonance Spectroscopy”, Arch Gen Psychiatry. Feb. 2007;64(2):193-200.
[cited by applicant]
Honack et al., “Sex differences in NMDA receptor mediated responses in rats”, Brain Res 1993; 620(1): 167-170.
[cited by applicant]
Howlett et al., “Prevention of Trauma and Stressor-Related Disorders: A Review. Neuropsychopharmacology”, Jan. 2016;41(1):357-69.
[cited by applicant]
Huang et al., “New Treatment Strategies of Depression: Based on Mechanisms Related to Neuroplasticity”, Neural Plast. 2017.
[cited by applicant]
International Search Report and Written Opinion dated Feb. 3, 2017 corresponding to International Patent Application No. PCT/US16/62562, 16 pages.
[cited by applicant]
International Search Report and Written Opinion of corresponding International Application PCT/US2018/059834, mailed on Feb. 25, 2019.
[cited by applicant]
International Search Report and Written Opinion of corresponding International Application PCT/US2018/060082, mailed on Jan. 24, 2019.
[cited by applicant]
Ionescu et al., “A single infusion of ketamine improves depression scores in patients with anxious bipolar depression”, Bipolar Disord. Jun. 2015;17(4):438-43.
[cited by applicant]
J Craig Nelson, “The evolving story of folate in depression and the therapeutic potential of I-methylfolate”, Am J Psychiatry. Dec. 2012;169(12):1223-5.
[cited by applicant]
Janice B. Schwartz, “The influence of sex on pharmacokinetics”, Clin Pharmacokinet 2003; 42(2): 107-121.
[cited by applicant]
Jha et al., “Can C-reactive protein inform antidepressant medication selection in depressed outpatients? Findings from the CO-MED trial”, Psychoneuroendocrinology, vol. 78, Apr. 2017, pp. 105-113.
[cited by applicant]
Jinnah et al., “Metabolic disorders of purine metabolism affecting the nervous system”, Handb Clin Neurol. 2013;113:1827-36.
[cited by applicant]
Johnson et al., “Metabolomics: beyond biomarkers and towards mechanisms”, Nat Rev Mol Cell Biol 17, 451-459 (2016).
[cited by applicant]
Joo et al., “Chronic immobilization stress induces anxiety- and depression-like behaviors and decreases transthyretin in the mouse cortex”, Neurosci Lett. 2009; 461(2):121-5.
[cited by applicant]
Kaddurah-Daouk et al., “Pretreatment metabotype as a predictor of response to sertraline or placebo in depressed outpatients: a proof of concept”, Transl Psychiatry. 2011;1(7).
[cited by applicant]
Kearns et al., “Early interventions for PTSD: a review”, Depress Anxiety. Oct. 2012;29(10):833-42.
[cited by applicant]
Kessler et al., “Posttraumatic stress disorder in the National Comorbidity Survey”, Arch Gen Psychiatry. Dec. 1995;52(12):1048-60.
[cited by applicant]
Kessler RC, Berglund P, Demler 0, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry. 2005; 62(6)…
[cited by applicant]
Khalid, “Treatment-resistant depression; therapeutic trends, challenges and future directions”, Patient Prefer Adherence, p. 369-388, May 6, 2012.
[cited by applicant]
Knoll et al., “Anxiolytic-Like Effects of k-Opioid Receptor Antagonists in Models of Unlearned and Learned Fear in Rats”, J Pharmacol Exp Ther. Dec. 2007;323(3):838-45.
[cited by applicant]
Kokras et al., “Sex differences in animal models of psychiatric disorders”, Br J Pharmacol 2014; 171 (20): 4595-4619.
[cited by applicant]
Kornstein SG, Schatzberg AF, Thase ME, Yonkers KA, McCullough JP, Keitner GI, et al. Gender differences in treatment response to sertraline versus imipramine in chronic depression. Am J Psychiatry_ 2000; 157(9): 1445-52.
[cited by applicant]
Lagamma et al., “Antidepressant but Not Prophylactic Ketamine Administration Alters Calretinin and Calbindin Expression in the Ventral Hippocampus”, Front Mol Neurosci. Nov. 6, 2018;11:404.
[cited by applicant]
Maier SF, Seligman MEP (1976): Learned helplessness: Theory and evidence. J Exp Psychol 105:3-46.
[cited by applicant]
Martinac et al., “Metabolic syndrome, activity of the hypothalamic-pituitary-adrenal axis and inflammatory mediators in depressive disorder”, Acta Clin Croat. Mar. 2014;53(1):55-71.
[cited by applicant]
Mastrodonato et al., “Ventral CA3 Activation Mediates Prophylactic Ketamine Efficacy Against Stress-Induced Depressive-like Behavior”, Biol Psychiaty. 2018; 84(11): 846-856.
[cited by applicant]
Mathew et al.: “Riluzole for relapse prevention following intravenous ketamine in treatment-resistant depression: a pilot randomized, placebo-controlled continuation trial”, International Journal of Neuropsychopharmacol…
[cited by applicant]
Matt McMillen, Ketamine: The Future of Depression Treatment? WedMD.com, Depression Health Center, Sep. 23, 2014 [retrieved from https://www.webmd.com/depression/news/20140923/ketamine-depression#1].
[cited by applicant]
McGhee LL, Maani CV, Garza TH, DeSocio PA, Gaylord KM, Black IH (2009): The effect of propranolol on posttraumatic stress disorder in burned service members. J Burn Care Res 30:92-97.
[cited by applicant]
McGowan et al., “Prophylactic ketamine alters nucleotide and neurotransmitter metabolism in brain and plasma following stress”, Neuropsychopharmacology 2018; 43 (9): 1813-1821.
[cited by applicant]
McGowan JC, LaGamma CT, Lim SC, Tsitsiklis M, Neria Y, Brachman RA, et al. Prophylactic Ketamine Attenuates Learned Fear. Neuropsychopharmacology_ 2017; 42(8): 1577-89.
[cited by applicant]
McNulty et al., “Compounded oral ketamine for severe depression, anxiety, and pain in a hospice patient with end-stage chronic obstructive pulmonary disease, cardiopulmonary failure, and severe renal insufficiency: a ca…
[cited by applicant]
Mendez-David et al., “Rapid anxiolytic effects of a 5-HT(4) receptor agonist are mediated by a neurogenesis-independent mechanism”, Neuropsychopharmacology 39 (6):1366-1378; 2014.
[cited by applicant]
Meyerhoff et al., “Cortical gamma-aminobutyric acid and glutamate in posttraumatic stress disorder and their relationships to self-reported sleep quality”, Sleep. May 1, 2014;37(5):893-900.
[cited by applicant]
Micheli et al., “Neurological disorders of purine and pyrimidine metabolism”, Curr Top Med Chem. 2011;11(8):923-47.
[cited by applicant]
Miller et al., “Personalized medicine in major depressive disorder—opportunities and pitfalls.” Metabolism: clinical and experimental vol. 62 Suppl 1,0 1 (2013): S34-9.
[cited by applicant]
Mion et al., “Ketamine Pharmacology: An Update (Pharmacodynamics and Molecular Aspects, Recent Findings)”, CNS Neurosci Ther. 2013; 19(6):370-80.
[cited by applicant]
Muller JM, Morelli E, Ansorge M, Gingrich JA (2011): Serotonin transporter deficient mice are vulnerable to escape deficits following inescapable shocks. Genes Brain Behav 10:166-175.
[cited by applicant]
Murrough et al, “Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A two-site randomized controlled trial”, Am. J. Psychiatry, 2013, vol. 170, Issue 10, pp. 1134-1142.
[cited by applicant]
Murrough et al., “Ketamine for rapid reduction of suicidal ideation: a randomized controlled trial”, Psychol Med. Dec. 2015;45(16):3571-80.
[cited by applicant]
Murrough et al.: “Rapid and longer-term antidepressant effects of repeated ketamine infusions in treatment-resistant major depression”: Biological Psychiatry, vol. 74 / Issue 4, pp. 250-256, 2013.
[cited by applicant]
National Research Council. “Depression in parents, parenting, and children: Opportunities to improve identification, treatment, and prevention.” (2009).
[cited by applicant]
Nikiforuk Agnieszka et al: “Ketamine prevents stress-induced cognitive inflexibility in rats”, Psychoneuroendocrinology, 2013, vol. 40, pp. 119-122.
[cited by applicant]
Palomero-Gallagher et al., “AMPA, kainate, and NMDA receptor densities in the hippocampus of untreated male rats and females in estrus and diestrus”, J Comp Neurol 2003; 459(4): 468-474.
[cited by applicant]
Pan et al., “GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour”, BMJ Case Rep. Jun. 9, 2011, 2011.
[cited by applicant]
Pan et al., “Neurometabolic Disorders: Potentially Treatable Abnormalities in Patients With Treatment Refractory Depression and Suicidal Behavior”, The American journal of psychiatry 174(1), 42-50.
[cited by applicant]
Pan et al., “Neuropsychiatric Symptoms in Inborn Errors of Metabolism: Incorporation of Genomic and Metabolomic Analysis into Therapeutics and Prevention”, Current genetic medicine reports 1(1), 65-70.
[cited by applicant]
Pan et al., “Effects of Ketamine on Metabolomics of Serum and Urine in Cynomolgus Macaques (
[cited by applicant]
Papakostas et al., “L-methylfolate as adjunctive therapy for SSRI-resistant major depression: results of two randomized, double-blind, parallel-sequential trials”, Am J Psychiatry. Dec. 2012;169(12):1267-74.
[cited by applicant]
Examination Report issued in AU Pat. Appln. No. 2020271839 dated Oct. 30, 2024.
[cited by applicant]
EP Communication pursuant to Article 94(3) EPC dated Mar. 14, 2024 issued in EP Pat. Appln. No. 20786878.7.
[cited by applicant]
Highland et al., “Group II metabotropic glutamate receptor blockade promotes stress resilience in mice”, Neuropsychopharmacology. Sep. 2019;44(10):1788-1796.
[cited by applicant]
Lucas et al., “Serotonin (4) (5-HT(4)) receptor agonists are putative antidepressants with a rapid onset of action”, Neuron, vol. 55, Issue 5, p. 712-725, Sep. 2007.
[cited by applicant]
Official Action issued in CN Pat. App. No. 2020800422524 dated Feb. 29, 2024.
[cited by applicant]
Official Action issued in JP Pat. Appln. No. 2021-560628 dated Mar. 5, 2024.
[cited by applicant]